A patient with a history of breast cancer and peripheral blood smear abnormalities (macrocytosis, teardrop cells, anisocytosis, polychromasia, ovalocytes, and burr cells) – should she be referred to her oncologist or to a hematologist for further evaluation?

Refer to Hematology

This patient with a history of breast cancer presenting with peripheral blood smear abnormalities (macrocytosis, teardrop cells, anisocytosis, polychromasia, ovalocytes, and burr cells) should be referred to hematology, not her oncologist, for urgent evaluation of potential bone marrow pathology including myelodysplastic syndrome, carcinocythemia, or cancer-related thrombotic microangiopathy.

Clinical Reasoning

The constellation of peripheral blood smear findings you describe—particularly teardrop cells (dacrocytes), anisocytosis, and polychromasia—suggests a primary bone marrow process rather than simple treatment-related changes from prior breast cancer therapy. These findings require specialized hematologic evaluation with bone marrow examination.

Why Hematology, Not Oncology?

Hematologists are specifically trained to:

• Interpret complex peripheral blood smear abnormalities 1
• Perform and interpret bone marrow aspirate and biopsy with appropriate cytogenetics 1
• Distinguish between primary hematologic malignancies (like MDS) and metastatic carcinomatosis
• Recognize rare but critical entities like carcinocythemia (circulating tumor cells mimicking leukemia) 2, 3, 4

Critical Differential Diagnoses to Rule Out

1. Myelodysplastic Syndrome (MDS)

• Requires bone marrow aspiration with iron stain, biopsy, and cytogenetics 1
• Initial evaluation must include: CBC with differential, reticulocyte count, peripheral smear examination, serum B12, RBC folate, serum ferritin, iron studies 1
• MDS can develop as therapy-related disease in breast cancer patients previously treated with chemotherapy

2. Carcinocythemia (Circulating Tumor Cells)

• Rare but life-threatening manifestation of metastatic breast cancer 2, 3
• Can mimic acute leukemia on peripheral smear 4
• Requires immunocytochemistry with cytokeratins (AE1/AE3) and epithelial markers (EpCAM) for confirmation 3, 4
• Often presents with disseminated intravascular coagulation and carries extremely poor prognosis 3

3. Bone Marrow Carcinomatosis

• Breast cancer (especially lobular type) can infiltrate bone marrow 4, 5
• May present with microangiopathic hemolytic anemia and schistocytes 5, 6
• Requires bone marrow biopsy with immunohistochemistry 5

Common Pitfall to Avoid

Do not assume these findings are simply treatment-related cytopenias or nutritional deficiencies. While breast cancer patients may develop anemia from chemotherapy, the specific smear findings you describe—particularly teardrop cells—indicate marrow infiltration or fibrosis requiring immediate hematologic workup 1.

Urgent Red Flags Requiring Same-Day Hematology Referral

• Any suspicion of circulating tumor cells (large atypical cells on smear)
• Schistocytes suggesting microangiopathic hemolytic anemia 5, 6
• Progressive cytopenias
• Constitutional symptoms (fever, night sweats, weight loss)
• Elevated LDH with hemolysis 4

The Hematologist's Workup Will Include

• Comprehensive peripheral smear review looking for atypical cells
• Bone marrow aspirate and biopsy with:
  • Morphologic assessment for dysplasia or metastatic cells
  • Cytogenetics
  • Flow cytometry (including non-hematologic markers if carcinocythemia suspected) 4
  • Immunohistochemistry if metastatic disease suspected 4, 5

Once the hematologist establishes the diagnosis, they will coordinate with oncology if the findings represent metastatic breast cancer rather than a primary hematologic disorder. However, the initial diagnostic evaluation requires hematologic expertise that most medical oncologists do not routinely perform.